VIENNA, Jan. 9, 2020 – PhagoMed Biopharma GmbH, (PhagoMed) a pre-clinical biotechnology company targeting bacterial pathogens in antibiotic resistance and microbiome settings, announced today that its chief executive officer, Alexander Belcredi, will present at the Biotech Sho...

Proprietary discovery and engineering platform to develop precision phage therapies First phage candidate expected to enter the clinic in 2022 Pipeline of antimicrobial-resistance and microbiome applications Estimated $12 Billion addressable market for multi-drug resistant in...